Trial Outcomes & Findings for The Zeaxanthin and Visual Function Study (NCT NCT00564902)
NCT ID: NCT00564902
Last Updated: 2012-03-29
Results Overview
Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).
COMPLETED
NA
60 participants
4 months
2012-03-29
Participant Flow
Subjects were patients in the Ophthalmology/Optometry Clinic North Chicago DVA Medical Center (now the James A. Lovell Federal Health Center)with early and moderate AMD retinopathy up to, but not including,high risk NEI AREDS retinopathy.
No enrolled participant was excluded before assignment to groups. Patients were asked to continue with their normal diet and were asked not to take any dietary supplement containing lutein (or zeaxanthin) beyond the 250 ug (1/4mg) commonly found in pabulum Centrum® type vitamins.
Participant milestones
| Measure |
Lutein
Lutein 9 mg per day
|
Lutein Zeaxanthin
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Overall Study
STARTED
|
10
|
25
|
25
|
|
Overall Study
4 Months
|
9
|
24
|
23
|
|
Overall Study
8 Months
|
9
|
22
|
21
|
|
Overall Study
12 Months
|
9
|
21
|
21
|
|
Overall Study
COMPLETED
|
9
|
21
|
21
|
|
Overall Study
NOT COMPLETED
|
1
|
4
|
4
|
Reasons for withdrawal
| Measure |
Lutein
Lutein 9 mg per day
|
Lutein Zeaxanthin
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
0
|
3
|
4
|
|
Overall Study
Death
|
1
|
1
|
0
|
Baseline Characteristics
The Zeaxanthin and Visual Function Study
Baseline characteristics by cohort
| Measure |
Lutein
n=10 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=25 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=25 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
Total
n=60 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
12 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
7 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
21 Participants
n=206 Participants
|
48 Participants
n=7 Participants
|
|
Age Continuous
|
73.9 years
STANDARD_DEVIATION 9 • n=99 Participants
|
75.8 years
STANDARD_DEVIATION 9 • n=107 Participants
|
74.4 years
STANDARD_DEVIATION 11 • n=206 Participants
|
74.9 years
STANDARD_DEVIATION 10 • n=7 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=99 Participants
|
24 Participants
n=107 Participants
|
24 Participants
n=206 Participants
|
57 Participants
n=7 Participants
|
|
Macular Pigment Optical Density
|
0.37 Density units of macular pigment
STANDARD_DEVIATION 0.05 • n=99 Participants
|
0.29 Density units of macular pigment
STANDARD_DEVIATION 0.06 • n=107 Participants
|
0.35 Density units of macular pigment
STANDARD_DEVIATION 0.04 • n=206 Participants
|
0.33 Density units of macular pigment
STANDARD_DEVIATION 0.05 • n=7 Participants
|
|
Early Treatment Diabetic Retinopathy Study distance visual acuity
|
93.3 units on a scale
STANDARD_DEVIATION 8 • n=99 Participants
|
86.8 units on a scale
STANDARD_DEVIATION 12 • n=107 Participants
|
88.3 units on a scale
STANDARD_DEVIATION 10 • n=206 Participants
|
88.7 units on a scale
STANDARD_DEVIATION 13 • n=7 Participants
|
|
Glare Recovery
|
52.9 Seconds
STANDARD_DEVIATION 16 • n=99 Participants
|
35.6 Seconds
STANDARD_DEVIATION 6 • n=107 Participants
|
26.7 Seconds
STANDARD_DEVIATION 5 • n=206 Participants
|
34.1 Seconds
STANDARD_DEVIATION 30 • n=7 Participants
|
|
Contrast Sensitivity Function Photopic Distance
|
212 units on a scale
STANDARD_DEVIATION 34 • n=99 Participants
|
204 units on a scale
STANDARD_DEVIATION 30 • n=107 Participants
|
201 units on a scale
STANDARD_DEVIATION 22 • n=206 Participants
|
204 units on a scale
STANDARD_DEVIATION 125 • n=7 Participants
|
|
Shape Discrimination
|
0.7 % modulation
STANDARD_DEVIATION 0.2 • n=99 Participants
|
0.7 % modulation
STANDARD_DEVIATION 0.1 • n=107 Participants
|
1 % modulation
STANDARD_DEVIATION 0.2 • n=206 Participants
|
0.8 % modulation
STANDARD_DEVIATION 0.8 • n=7 Participants
|
|
6.5 degrees Tritan threshold
|
4.9 (dB)
STANDARD_DEVIATION 4 • n=99 Participants
|
8.6 (dB)
STANDARD_DEVIATION 12 • n=107 Participants
|
6 (dB)
STANDARD_DEVIATION 9 • n=206 Participants
|
6.9 (dB)
STANDARD_DEVIATION 10 • n=7 Participants
|
|
100% Kinetic Field
|
5514 Units on a scale (0 to 6000)
STANDARD_DEVIATION 2074 • n=99 Participants
|
1717 Units on a scale (0 to 6000)
STANDARD_DEVIATION 765 • n=107 Participants
|
2649 Units on a scale (0 to 6000)
STANDARD_DEVIATION 750 • n=206 Participants
|
2738 Units on a scale (0 to 6000)
STANDARD_DEVIATION 4471 • n=7 Participants
|
PRIMARY outcome
Timeframe: 4 monthsPopulation: All participants in all arms were tested
Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=24 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=23 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Macular Pigment Optical Density
|
0.48 Density units of Macular Pigment (du)
Standard Error .05
|
0.38 Density units of Macular Pigment (du)
Standard Error .06
|
0.42 Density units of Macular Pigment (du)
Standard Error .04
|
PRIMARY outcome
Timeframe: 8 monthsPopulation: All participants in all arms were tested
Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=22 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Macular Pigment Optical Density
|
0.48 Density units of Macular Pigment (du)
Standard Error 0.05
|
0.44 Density units of Macular Pigment (du)
Standard Error 0.06
|
0.46 Density units of Macular Pigment (du)
Standard Error 0.04
|
PRIMARY outcome
Timeframe: 12 monthsPopulation: All participants in all arms were tested
Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering light emitting diodes and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated.
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Macular Pigment Optical Density
|
0.54 Density units of Macular Pigment (du)
Standard Error 0.05
|
0.52 Density units of Macular Pigment (du)
Standard Error 0.06
|
0.48 Density units of Macular Pigment (du)
Standard Error 0.04
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Eyes of all participants still in the trial were measured
We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
SHAPE Discrimination
|
0.5 % modulation
Standard Deviation .24
|
0.6 % modulation
Standard Deviation 0.25
|
0.6 % modulation
Standard Deviation .46
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Eyes of all patients still in the trial were measured
Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Early Treatment Diabetic Retinopathy Study Distance Visual Acuity
|
98.9 units on a scale
Standard Error 5.7
|
92.8 units on a scale
Standard Error 5.9
|
96.8 units on a scale
Standard Error 8.35
|
SECONDARY outcome
Timeframe: 12 MonthsPopulation: Eyes of all patients still in the trial were measured
Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Glare Recovery
|
25.2 Seconds
Standard Error 28.5
|
14.85 Seconds
Standard Error 22
|
16.65 Seconds
Standard Error 10.25
|
SECONDARY outcome
Timeframe: 12 MonthsPopulation: Eyes of all patients still in the trial were measured
Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 \& 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
Contrast Sensitivity Function Photopic Distance
|
310.5 units on a scale
Standard Error 33.8
|
247.1 units on a scale
Standard Error 35
|
254.7 units on a scale
Standard Error 35.2
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: Eyes of all patients still in the trial were measured
The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
6.5 Degrees Tritan Threshold
|
4.46 dB
Standard Error 1.08
|
8.37 dB
Standard Error 1.39
|
3.45 dB
Standard Error 1.09
|
SECONDARY outcome
Timeframe: 12 MonthsPopulation: Eyes of all patients still in the trial were measured
Scotomas within the central 20 degree central macula visual field sensitivity was assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outlined the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculated summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).
Outcome measures
| Measure |
Lutein
n=9 Participants
Lutein 9 mg per day
|
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
|
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
|
|---|---|---|---|
|
100% Kinetic Field
|
2704 Units on a scale (0 to 6000)
Standard Error 1745
|
2207 Units on a scale (0 to 6000)
Standard Error 210
|
1129 Units on a scale (0 to 6000)
Standard Error 650
|
Adverse Events
Lutein
Lutein Zeaxanthin
Zeaxanthin
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Stuart P. Richer
James A. Lovell Federal Health Care Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place